BR112021019817A2 - Compostos de pirrol - Google Patents
Compostos de pirrolInfo
- Publication number
- BR112021019817A2 BR112021019817A2 BR112021019817A BR112021019817A BR112021019817A2 BR 112021019817 A2 BR112021019817 A2 BR 112021019817A2 BR 112021019817 A BR112021019817 A BR 112021019817A BR 112021019817 A BR112021019817 A BR 112021019817A BR 112021019817 A2 BR112021019817 A2 BR 112021019817A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutically acceptable
- pyrrole compounds
- compounds
- formula
- methods
- Prior art date
Links
- 150000003233 pyrroles Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/094—Esters of phosphoric acids with arylalkanols
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962828919P | 2019-04-03 | 2019-04-03 | |
| US201962932686P | 2019-11-08 | 2019-11-08 | |
| PCT/US2020/026116 WO2020205934A1 (en) | 2019-04-03 | 2020-04-01 | Pyrrole compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021019817A2 true BR112021019817A2 (pt) | 2021-12-07 |
Family
ID=72667046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021019817A BR112021019817A2 (pt) | 2019-04-03 | 2020-04-01 | Compostos de pirrol |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US11191747B2 (https=) |
| EP (2) | EP3947349B1 (https=) |
| JP (3) | JP7627008B2 (https=) |
| KR (2) | KR102933784B1 (https=) |
| CN (4) | CN114258391A (https=) |
| AU (2) | AU2020253444C1 (https=) |
| BR (1) | BR112021019817A2 (https=) |
| CA (1) | CA3134635A1 (https=) |
| CL (1) | CL2021002575A1 (https=) |
| CO (1) | CO2021014210A2 (https=) |
| DK (1) | DK3947349T3 (https=) |
| FI (1) | FI3947349T3 (https=) |
| GE (2) | GEAP202515762A (https=) |
| IL (1) | IL286902B2 (https=) |
| MA (1) | MA55564A (https=) |
| MX (1) | MX2021012105A (https=) |
| PE (1) | PE20220252A1 (https=) |
| PH (1) | PH12021552513A1 (https=) |
| SG (1) | SG11202110718PA (https=) |
| TW (1) | TWI846853B (https=) |
| UA (1) | UA129029C2 (https=) |
| WO (1) | WO2020205934A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021012105A (es) | 2019-04-03 | 2021-11-03 | Aligos Therapeutics Inc | Compuestos de pirrol. |
| CN114685514A (zh) * | 2020-12-29 | 2022-07-01 | 广东东阳光药业有限公司 | 新型酰胺吡咯类化合物及其在药物中的应用 |
| WO2022156758A1 (zh) * | 2021-01-22 | 2022-07-28 | 广东东阳光药业有限公司 | 新型酰胺吡咯类化合物及其在药物中的用途 |
| EP4399217A2 (en) | 2021-09-08 | 2024-07-17 | Aligos Therapeutics, Inc. | Modified short interfering nucleic acid (sina) molecules and uses thereof |
| CN118974014B (zh) * | 2022-03-17 | 2026-01-27 | 成都微芯药业有限公司 | 吡咯酰胺类化合物及其制备方法和用途 |
| CN116120219A (zh) * | 2022-12-27 | 2023-05-16 | 吉斯凯(苏州)制药有限公司 | 一种多取代吡咯类化合物及其制备方法和在制备hbv衣壳蛋白抑制剂中的应用 |
| EP4654973A1 (en) * | 2023-01-26 | 2025-12-03 | Aligos Therapeutics, Inc. | Hepatitis b combination therapies |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4784782A (en) | 1986-03-27 | 1988-11-15 | The Lubrizol Corporation | Heterocyclic compounds useful as additives for lubricant and fuel compositions |
| HUP0302918A2 (hu) | 2000-07-17 | 2003-12-29 | Ranbaxy Laboratories Limited | Mikrobaellenes oxazolidinonszármazékok és a vegyületeket tartalmazó gyógyászati készítmények és eljárás a vegyületek előállítására |
| ATE427948T1 (de) | 2001-04-24 | 2009-04-15 | Purdue Research Foundation | Folat-mimetika und deren folatrezeptorbindende konjugate |
| US6956040B2 (en) | 2001-07-16 | 2005-10-18 | Ranbaxy Laboratories Limited | Oxazolidinone piperazinyl derivatives as potential antimicrobials |
| GB0119172D0 (en) | 2001-08-06 | 2001-09-26 | Melacure Therapeutics Ab | Phenyl pyrrole derivatives |
| PL377314A1 (pl) | 2002-12-20 | 2006-01-23 | Amgen Inc. | Modulatory astmy i zapaleń na tle alergicznym |
| US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| GB2398299A (en) | 2003-02-13 | 2004-08-18 | Melacure Therapeutics Ab | Pharmaceutically active phenyl-pyrrole derivatives |
| US20070191336A1 (en) | 2003-12-24 | 2007-08-16 | Flynn Daniel L | Anti-inflammatory medicaments |
| US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| CN100519555C (zh) | 2004-03-13 | 2009-07-29 | Tmrc株式会社 | 将dna的特定碱基序列烷基化的新吲哚衍生物和使用其的烷基化剂以及药剂 |
| US20060102471A1 (en) | 2004-11-18 | 2006-05-18 | Karl Maurer | Electrode array device having an adsorbed porous reaction layer |
| US20060105355A1 (en) | 2004-11-18 | 2006-05-18 | Karl Maurer | Electrode array device having an adsorbed porous reaction layer having a linker moiety |
| WO2006092059A1 (en) | 2005-03-04 | 2006-09-08 | Fan Wu | Design and synthesis of novel antimicrobials |
| US20100234379A1 (en) | 2005-07-28 | 2010-09-16 | Bahr Ben A | Dual modulation of endocannabinoid transport and fatty-acid amide hydrolase for treatment of excitotoxicity |
| US20070065877A1 (en) | 2005-09-19 | 2007-03-22 | Combimatrix Corporation | Microarray having a base cleavable succinate linker |
| ES2565683T3 (es) | 2006-09-15 | 2016-04-06 | Xcovery, Inc. | Compuestos inhibidores de quinasa |
| CA2688136A1 (en) | 2007-06-08 | 2008-12-11 | Advinus Therapeutics Private Limited | Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application |
| AU2008266515B2 (en) | 2007-06-18 | 2014-05-01 | Sanofi | Pyrrole derivatives as P2Y12 antagonists |
| CA2754492A1 (en) | 2009-03-05 | 2010-09-10 | Purdue Research Foundation | Method for early imaging of atherosclerosis |
| EP2408770B1 (en) | 2009-03-20 | 2014-11-05 | University Of Virginia Patent Foundation | Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials |
| JP2013508413A (ja) | 2009-10-22 | 2013-03-07 | ヴァンダービルト ユニバーシティー | ｍＧｌｕＲ４アロステリック増強剤、組成物、および神経機能不全を治療する方法 |
| EP2568809A4 (en) | 2010-05-12 | 2013-11-06 | Univ Vanderbilt | HETEROCYCLIC ALLOSTERE SULFON MGLUR4 POTENTIATORS, COMPOSITIONS AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTIONS |
| CN103068814B (zh) | 2010-06-15 | 2015-11-25 | 拜耳知识产权有限责任公司 | 邻氨基苯甲酸衍生物 |
| PL2616444T3 (pl) | 2010-09-14 | 2016-04-29 | Inst Biochemii I Biofizyki Pan | Związki będące modulatorami zmutowanego białka CFTR oraz ich zastosowanie w leczeniu chorób związanych z zaburzeniami w funkcjonowaniu białka CFTR |
| WO2012047525A2 (en) | 2010-09-27 | 2012-04-12 | Endocyte, Inc. | Folate conjugates for treating inflammation of the eye |
| WO2012078902A2 (en) | 2010-12-08 | 2012-06-14 | Proteostasis Therapeutics, Inc. | Proteostasis regulators |
| WO2012087976A2 (en) | 2010-12-21 | 2012-06-28 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| WO2012154880A1 (en) | 2011-05-09 | 2012-11-15 | Proteostasis Therapeutics, Inc. | Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases |
| US20130072473A1 (en) | 2011-05-09 | 2013-03-21 | Proteostasis Therapeutics, Inc. | Compounds for treating protein folding disorders |
| HUE044867T2 (hu) | 2011-05-12 | 2019-11-28 | Proteostasis Therapeutics Inc | Proteosztázis szabályzók |
| JP5977347B2 (ja) | 2011-07-01 | 2016-08-24 | バルーク エス．ブルームバーグ インスティテュート | Ｈｂｖ感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体 |
| US8835640B1 (en) | 2011-11-16 | 2014-09-16 | Paresh T. Gandhi | Nicotine derivatives |
| EP2804605A4 (en) | 2012-01-20 | 2015-07-08 | Acucela Inc | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES |
| EP3345597A3 (en) | 2012-09-19 | 2018-08-22 | Faller & Williams Technology, LLC | Pkc delta inhibitors for use as therapeutics |
| TWI733288B (zh) | 2013-05-17 | 2021-07-11 | 愛爾蘭商健生科學愛爾蘭無限公司 | 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途 |
| HRP20180791T1 (hr) * | 2013-07-25 | 2018-09-07 | Janssen Sciences Ireland Uc | Glioksamid supstituirani derivati pirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b |
| CA2923712C (en) * | 2013-10-23 | 2021-11-02 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| CN104672221B (zh) | 2013-11-29 | 2018-01-23 | 中国科学院上海有机化学研究所 | 一种氟代苯并杂环‑杂芳环结构的合成方法 |
| US10040780B2 (en) | 2014-03-03 | 2018-08-07 | The Regents Of The University Of California | Mcl-1 antagonists |
| DE102014108210A1 (de) | 2014-06-11 | 2015-12-17 | Dietrich Gulba | Rodentizid |
| US20160166679A1 (en) | 2014-12-12 | 2016-06-16 | Purdue Research Foundation | Method of treatment using folate conjugates and tyrosine kinase inhibitors |
| KR101726059B1 (ko) | 2015-07-28 | 2017-04-12 | 한양대학교 산학협력단 | 디피롤 유도체와 암모늄 염을 포함하는 브롬화수소 가스 검출용 조성물 및 이를 포함하는 브롬화수소 가스 검출용 색변환 센서 |
| KR101726060B1 (ko) | 2015-07-28 | 2017-04-12 | 한양대학교 산학협력단 | 디피롤 유도체와 금속 염을 포함하는 염화수소 가스 검출용 조성물 및 이를 포함하는 염화수소 가스 검출용 색변환 센서 |
| WO2017081615A1 (en) | 2015-11-09 | 2017-05-18 | Wockhardt Limited | 7-oxo -6-(sulfooxy)- 1,6-diazabicyclo [3.2.1] octane containing compounds and their use in treatment of bacterial infections |
| CO2018009382A2 (es) * | 2016-03-09 | 2018-09-20 | Univ Emory | Eliminación del virus de la hepatitis b con agentes antivirales |
| JOP20190024A1 (ar) * | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| CN108250121A (zh) | 2016-12-28 | 2018-07-06 | 上海长森药业有限公司 | 磺酰胺-芳基酰胺类化合物及其治疗乙型肝炎的药物用途 |
| WO2019185016A1 (zh) * | 2018-03-30 | 2019-10-03 | 正大天晴药业集团股份有限公司 | 含有n杂五元环的衣壳蛋白装配抑制剂、其药物组合物和用途 |
| US20230056135A1 (en) | 2018-10-05 | 2023-02-23 | Emory University | Monomer and multimeric anti-hbv agents |
| WO2020169784A1 (en) | 2019-02-22 | 2020-08-27 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases |
| MX2021012105A (es) | 2019-04-03 | 2021-11-03 | Aligos Therapeutics Inc | Compuestos de pirrol. |
| EP4245372A3 (en) | 2019-11-13 | 2023-11-22 | Xi'An Xintong Pharmaceutical Research Co., Ltd. | Hbv inhibitor and use thereof |
| CN114685514A (zh) | 2020-12-29 | 2022-07-01 | 广东东阳光药业有限公司 | 新型酰胺吡咯类化合物及其在药物中的应用 |
-
2020
- 2020-04-01 MX MX2021012105A patent/MX2021012105A/es unknown
- 2020-04-01 CA CA3134635A patent/CA3134635A1/en active Pending
- 2020-04-01 GE GEAP202515762A patent/GEAP202515762A/en unknown
- 2020-04-01 WO PCT/US2020/026116 patent/WO2020205934A1/en not_active Ceased
- 2020-04-01 CN CN202080028131.4A patent/CN114258391A/zh active Pending
- 2020-04-01 CN CN202511436317.4A patent/CN121085825A/zh active Pending
- 2020-04-01 UA UAA202105907A patent/UA129029C2/uk unknown
- 2020-04-01 EP EP20784496.0A patent/EP3947349B1/en active Active
- 2020-04-01 SG SG11202110718PA patent/SG11202110718PA/en unknown
- 2020-04-01 PE PE2021001658A patent/PE20220252A1/es unknown
- 2020-04-01 EP EP26163262.4A patent/EP4733305A2/en active Pending
- 2020-04-01 DK DK20784496.0T patent/DK3947349T3/da active
- 2020-04-01 KR KR1020217035886A patent/KR102933784B1/ko active Active
- 2020-04-01 IL IL286902A patent/IL286902B2/en unknown
- 2020-04-01 CN CN202511435986.XA patent/CN121108187A/zh active Pending
- 2020-04-01 GE GEAP202015762A patent/GEP20257772B/en unknown
- 2020-04-01 PH PH1/2021/552513A patent/PH12021552513A1/en unknown
- 2020-04-01 FI FIEP20784496.0T patent/FI3947349T3/fi active
- 2020-04-01 BR BR112021019817A patent/BR112021019817A2/pt unknown
- 2020-04-01 CN CN202511330314.2A patent/CN121108034A/zh active Pending
- 2020-04-01 KR KR1020267006069A patent/KR20260036605A/ko active Pending
- 2020-04-01 MA MA055564A patent/MA55564A/fr unknown
- 2020-04-01 US US16/837,515 patent/US11191747B2/en active Active
- 2020-04-01 TW TW109111398A patent/TWI846853B/zh active
- 2020-04-01 AU AU2020253444A patent/AU2020253444C1/en active Active
- 2020-04-01 JP JP2021559054A patent/JP7627008B2/ja active Active
-
2021
- 2021-10-01 CL CL2021002575A patent/CL2021002575A1/es unknown
- 2021-10-25 CO CONC2021/0014210A patent/CO2021014210A2/es unknown
- 2021-11-16 US US17/455,178 patent/US11771680B2/en active Active
-
2023
- 2023-08-22 US US18/453,887 patent/US12599582B2/en active Active
-
2024
- 2024-06-25 JP JP2024101773A patent/JP7710215B2/ja active Active
-
2025
- 2025-06-30 JP JP2025110439A patent/JP7811768B2/ja active Active
- 2025-08-13 AU AU2025217289A patent/AU2025217289A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021019817A2 (pt) | Compostos de pirrol | |
| BR112022025037A2 (pt) | Compostos antivirais para tratar infecções por coronavírus, picornavírus e norovírus | |
| BR112021019465A2 (pt) | Compostos que têm como alvo prmt5 | |
| JOP20210319B1 (ar) | مركبات بيروليدين | |
| BR112022018140A2 (pt) | Compostos pirimidoheterocíclicos e aplicação dos mesmos | |
| MX2023007192A (es) | Inhibidores de prmt5. | |
| BR112022000019A2 (pt) | Composto da fórmula, composição farmacêutica e método de tratamento de câncer | |
| CL2024000067A1 (es) | Compuestos antivirales | |
| BR112022002520A2 (pt) | Piperidinil-metil-purina-aminas como inibidores de nsd2 e agentes anticâncer | |
| MX2024009886A (es) | Derivados de quinolina como inhibidores de integrina alfa4beta7. | |
| BR112012003578A8 (pt) | Composto, sal farmaceuticamente aceitável, sal de sulfato, composição farmacêutica, método para tratar uma infecção viral, e, uso de um composto ou sal | |
| BRPI0806789B8 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
| BR112021011325A2 (pt) | Derivados de rapamicina | |
| BR112022018067A2 (pt) | Aminas de pirrolopirimidina como inibidores de complemento | |
| BR112021023967A2 (pt) | Compostos tricíclicos | |
| BR112022020933A2 (pt) | Inibidores de replicação do vírus da imunodeficiência humana | |
| BR112022006608A2 (pt) | Inibidores orais do fator d do complemento | |
| JOP20250214A1 (ar) | مشتقات هيدروكينازولين لعلاج مرض أو اضطراب | |
| BR112022015925A2 (pt) | Combinações de compostos beta-lactâmicos, probenecida e ácido valproico e usos dos mesmos | |
| BR112022017779A2 (pt) | Imunomodulação de azaletos de o-het-arila | |
| JOP20240119A1 (ar) | مشتقات نافثيريدينون لمعالجة مرض أو اضطراب | |
| EA202190458A1 (ru) | Составы, содержащие дендример | |
| MX2021014544A (es) | Derivados de aminoglucosidos antibacterianos. | |
| EA202192382A1 (ru) | Соединения, нацеленные на prmt5 | |
| JOP20250073A1 (ar) | مركبات سلفوكسيمين كمثبط دياسيتيلاز هيستون 6، وتركيبة صيدلانية تشتمل عليها |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |